Phase 2 Depression and Anxiety Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 64 years old at the time of joining the study
• People who have been diagnosed with long-term (chronic) depression — either recurring moderate or severe depressive episodes without full recovery between them, or a single depressive episode that has lasted two or more years
• People whose depression has continued even after trying at least two different antidepressant medications from two different medication types
• People whose depression has continued even after completing at least 12 sessions of talking therapy (such as psychoanalysis, depth psychology-based therapy, or cognitive behavioural therapy)
• People who are able to understand and voluntarily sign a consent form before any study procedures begin
• People who are able to attend all required study visits and follow the study's requirements
• Women who could become pregnant must agree to use two reliable forms of contraception at the same time, or to avoid heterosexual contact, from the start of the study until 28 days after the last treatment
• Men must agree to use a latex condom during any sexual contact with a woman who could become pregnant, from the first treatment until 65 days after the last treatment — this applies even after a vasectomy — and must also agree not to donate semen or sperm during that same period
• All participants must agree not to donate blood from the first treatment until 28 days after the last treatment
• All participants must agree not to share their study medication with anyone else

Who may not be able to join:

• People whose primary diagnosis is a current substance misuse problem (such as drug or alcohol misuse)
• People with certain neurological conditions such as stroke, brain tumour, brain infection, or an autoimmune brain disease
• People with conditions that cause increased pressure inside the skull, such as from a head injury
• People with problems with blood circulation in the brain
• People who are pregnant or breastfeeding
• People currently participating in another clinical study, or who have recently taken an experimental treatment that could affect this study's results
• People who have epilepsy
• People who have had an allergic reaction to a similar medication to the one used in this study, or to any of its ingredients
• People who have previously been treated with ketamine hydrochloride (the study medication) or a therapy called CBASP
• People with high blood pressure that is untreated or not well controlled (blood pressure readings above 150/100 mmHg on repeated measurement, or a lifelong diagnosis of high blood pressure)
• People with an overactive thyroid gland that is untreated or not well controlled
• People who have had unstable chest pain (unstable angina) or a heart attack within the last six months
• People with raised pressure in the eye (glaucoma) or a penetrating eye injury
• People who have had surgery or procedures in the upper airway (nose, mouth, or throat area)

Important: Always verify eligibility with the trial site directly before applying.